Polyvascular Disease in Patients Presenting with Acute Coronary Syndrome: Its Predictors and Outcomes

Table 2

Management and clinical outcomes in patients with acute coronary syndrome with and without polyvascular disease.

	ACS alone (𝑛=7261)	Polyvascular disease (𝑛=428)	P value
On admission therapy %
Aspirin	38	74	0.001
Clopidogrel	11	23	0.001
𝛽-blockers	28	43.5	0.001
ACE inhibitors	24	46	0.001
Statins	29	58	0.001
Thrombolysis*	52	20	0.001
Unfractionated heparin	42	40	0.46
LMW heparin	37	41	0.12
Glycoprotein inhibitors	7.7	8	0.82
During hospitalization %
Aspirin	98.5	96	0.001
Clopidogrel	76	81	0.02
β blockers	75	68	0.002
ACE inhibitors	71	69	0.31
Statins	95	92.5	0.03
Coronary angiography	39	31	0.002
PCI	22	12.4	0.001
Discharge medications %
Aspirin	96	92	0.001
Clopidogrel	68	70	0.32
β blockers	80	74	0.01
ACE inhibitors	72	63.5	0.001
Statins	92	85	0.001
Outcomes %
Reischemia	15	23.4	0.001
Heart failure	11.6	29.7	0.001
Stroke	0.6	2.3	0.001
Bleedings	0.6	0.9	0.31
Hospital death	4.2	9.1	0.001
1-month death	7.4	16.3	0.001
12-month death	11.2	24.6	0.001

*ST-elevation MI, PCI: percutaneous coronary intervention.